January 9, 2020 03:01 AM ESTUpdated 03:29 AM
Financing
Startups

Shreds of Tregs: French biotech wins Medicxi back­ing to kill the rogue im­muno­sup­pres­sive agent to fight can­cer

Natalie Grover

Reporter

Ex­ist­ing CD25 drugs tend to thwart IL-2 sig­nal­ing, which is im­per­a­tive to shap­ing the body’s im­mune re­sponse. But a French drug de­vel­op­er thinks it has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times